SEROTONIN AND 5-HIAA IN THE BLOOD AS MARKERS OF ENDOTHELIAL DYSFUNCTION IN MODELING CARDIOPULMONARY DISEASES
DOI: 10.22138/2500-0918-2024-21-4-399-408
D.F. Bilalova, R.R. Nigmatullina, L.R. Khusnutdinova
FSBEI HE Kazan SMU MON Russia, Kazan, Russian Federation
Abstract. The study analyzed the relationship between the concentration of serotonin and 5-HIAA in blood plasma and the development of pulmonary arterial hypertension in immature rats. Objective: To determine the concentration of serotonin and 5-HIAA in blood plasma and platelets in immature rats in the monocrotaline model of pulmonary hypertension. Materials and Methods. In the study, 4-week-old Wistar rats were given a single subcutaneous injection of monocrotaline (MCT) at a dose of 60 mg/kg to form a model of pulmonary arterial hypertension. The concentration of serotonin (5-HT) and 5-hydroxy-3-indoleacetic acid (5-HIAA) in blood plasma and platelets was determined using HPLC. The development of pulmonary hypertension was assessed weekly for 4 weeks until the rats reached 8 weeks of age. Results. One day after MCT administration, the serotonin concentration in the blood plasma of the experimental group was 317.1±80.6 pmol/mL, more than double that of the control group (157.9±79.1 pmol/mL). Elevated serotonin concentrations persisted throughout the observation period, exceeding control values by 279%, 386%, 354%, and 318% at 1, 2, 3, and 4 weeks, respectively, with high statistical significance. The concentration of 5-HIAA was higher than that of the control group and remained elevated over 4 weeks, exceeding the control group values by 156%, 205%, 155%, and 201%, respectively. An increase in 5-HIAA concentration in platelets was noted immediately after MCT administration, continuing for the first two weeks (48.15±9.44, 45.18±9.07, 43.76±4.02 pmol/mL compared to 23.26±2.42, 22.69±5.42, 24.86±2.27 in the control group). In weeks 3 and 4, there was a sharp decrease by 1.6-2.2 times in serotonin and 5-HIAA concentrations compared to the control group. Conclusion. A connection between increased levels of 5-HT and 5-HIAA with the progression of PAH was established. The rise in plasma serotonin levels activates its metabolism, leading to an increase in 5-HIAA concentration in plasma. This relationship confirms the dependency between elevated serotonin and its metabolite concentrations with the development and progression of pulmonary arterial hypertension. Moreover, it suggests that MCT activates processes related to serotonergic regulation, leading to the formation and progression of PAH in immature rats in the monocrotaline model, initiating a «serotonin loop» characterized by an initial serotonin elevation that further contributes to pulmonary arterial hypertension development. Given the obtained data, serotonin and 5-HIAA concentrations can be considered peripheral biomarkers of pulmonary arterial hypertension.
Keywords: serotonin, pulmonary hypertension, monocrotaline, immature rats, 5-hydroxyindoleacetic acid, plasma, platelets
No conflict of interest.
Corresponding author’s contact information:
Diana F. Bilalova
Diana_bilalova@hotmail.com
Received
For citation: Bilalova D.F., Nigmatullina R.R., Khusnutdinova L.R.Serotonin and 5-HIAA in the blood as markers of endothelial dysfunction in modeling cardiopulmonary diseases. [Online] Vestn. Ural. Med. Akad. Nauki. = Journal of Ural Medical Academic Science. 2024, Vol. 21, no. 4, pp. 399–408. DOI: 10.22138/2500-0918-2024-21-4-399-408 (In Russ)
REFERENCES
5. Mustafin A.A., Mirolyubov L.M., Nigmatullina R.R. The serotonergic system in the pathogenesis of pulmonary arterial hypertension in children with congenital heart defects [Serotoninergicheskaja sistema v patogeneze formirovanija legochnoj arterial’noj gipertenzii u detej s vrozhdennymi porokami serdca]. Kazan Medical Journal= Kazanskij medicinskij zhurnal. 2009; 90(3): 309-313.(In Russ)
6. Humbert M., Kovacs G., Hoeper M.M., Badagliacca R., Berger R.M.F., Brida M., Carlsen J., Coats A.J.S., Escribano-Subias P., Ferrari P., Ferreira D.S., Ghofrani H.A., Giannakoulas G., Kiely D.G., Mayer E., Meszaros G., Nagavci B., Olsson K.M., Pepke-Zaba J., Quint J.K., Rådegran G., Simonneau G., Sitbon O., Tonia T., Toshner M., Vachiery J.L., Vonk Noordegraaf A., Delcroix M., Rosenkranz S.; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022; 43(38):3618-3731. doi:10.1093/eurheartj/ehac237.
7. Launay J.-M. Serotonin and the cardiovascular system: role of the serotoninergic 5-HT 2B receptor. Bulletin De l’Academie Nationale De Medecine. 2003; 187(1):117-125.
8. Bilalova D.F. 5-HT2B receptor expression and its role in an embryonic development of human myocardium. Journal of Electrocardiology. 2013; 46(4):e7. doi:10.1016/j.jelectrocard.2013.05.028.
9. Bilalova D., Nigmatullina R., Mustafin A. Role of serotonin and its metabolite 5-hiaa in the development of pulmonary hypertension. New approaches to treatment and non-invasive diagnostics? Journal of Hypertension. 2022; 40(1):e156.
10. Mustafin A.A., Nigmatullina R.R., Bilalova D.F. Serotonin as the main cause of pulmonary hypertension: from hypothesis to medical practice. Modern Science: Actual Problems of Theory and Practice. Series: Natural and technical sciences. 2018; 3:107-111.
11. Mustafin A.A., Nigmatullina R.R., Mirolyubov L.M. Functional activity of 5-HT4 receptors in children with congenital heart disease. Experimental Methods for Clinical Practice. 2006; 142(6):717-719. doi:10.1007/s10517-006-0460-1.
12. Bilalova D., Mindubayeva F., Nigmatullina R., Salikhova Y. Monocrotaline model of Pulmonary hypertension in immature rats from the perspective of Serotonergic regulation. Research Journal of Pharmacy and Technology. 2023; 16(8):3915-3920. doi:10.52711/0974-360X.2023.00644.
13. Ryan J.J., Marsboom G., Archer S.L. Rodent models of group 1 pulmonary hypertension. Handbook of Experimental Pharmacology. 2013; 218:105-149. doi:10.1007/978-3-642-38664-0_5.
14. West J., Hemnes A. Experimental and Transgenic Models of Pulmonary Hypertension. Comprehensive Physiology. Ed. R.Terjung. Wiley, 2011; 769-782.
15. Gomez-Arroyo J.G., Farkas L., Alhussaini A.A., Farkas D., Kraskauskas D., Voelkel N.F., Bogaard H.J. The monocrotaline model of pulmonary hypertension in perspective. Am J Physiol Lung Cell Mol Physiol. 2012; 302(4):L363-9. doi:10.1152/ajplung.00212.2011.
16. Bilalova D.F. 5-HT2B receptor expression and its role in an embryonic development of human myocardium. Journal of Electrocardiology. 2013; 46(4):e7.
17. Bilalova D.F., Nigmatullina R.R., Mustafin A.A. 5-HT2 receptors and 5-GIUK therapeutic targets for assessing the severity, progression and effectiveness of treatment in immature male rats in a monocrotaline model of pulmonary hypertension [5-HT2-receptory i 5-GIUK – terapevticheskie misheni ocenki tjazhesti, progressirovanija i jeffektivnosti lechenija u nepolovozrelyh samcov krys v monokrotalinovoj modeli legochnoj gipertenzii]. I.M.Sechenov Russian Journal of Physiology=Rossijskij fiziologicheskij zhurnal im. I.M.Sechenova. 2023; 109(8):1045-1055. doi:10.31857/S0869813923080022.(In Russ)
18. On responsible treatment of animals and on amendments to certain legislative acts of the Russian Federation [Ob otvetstvennom obrashhenii s zhivotnymi i o vnesenii izmenenij v otdel’nye zakonodatel’nye akty Rossijskoj Federacii]. Federal Law of the Russian Federation No. 498 dated 12/27/2018. Russian newspaper=Rossiyskaya gazeta. 2018; 295.(In Russ)
19. Ormandy E.H., Weary D.M., Cvek K., Fisher M., Herrmann K., Hobson-West P., McDonald M., Milsom W., Rose M., Rowan A., Zurlo J., von Keyserlingk M.A.G. Animal Research, Accountability, Openness and Public Engagement: Report from an International Expert Forum. Animals (Basel). 2019; 9(9):622. doi:10.3390/ani9090622.
20. Krasilshchikova M.S., Belozertseva I.V. Directives 2010/63/Her of the European Parliament and of the Council of the European Union on the protection of animals used for scientific purposes [Direktiva 2010/63/Ei Evropejskogo parlamenta i Soveta Evropejskogo Sojuza po ohrane zhivotnyh, ispol’zuemyh v nauchnyh celjah]. SPb. 2012; 48.(In Russ)
21. Nigmatullina R.R., Kirillova V.V., Jourjikiya R.K., Mukhamedyarov M.A., Kudrin V.S., Klodt P.M., Palotás A. Disrupted Serotonergic and Sympathoadrenal Systems in Patients with Chronic Heart Failure May Serve as New Therapeutic Targets and Novel Biomarkers to Assess Severity, Progression and Response to Treatment. Cardiology. 2009; 113(4):277-286. doi:10.1159/000205962.
Authors
Diana F. Bilalova
Federal State Budgetary Educational Institution of Higher Education «Kazan Medical University» of the Ministry of Healthcare of the Russian Federation (FSBEI HE Kazan SMU MON Russia)
Postgraduate student, Department of Normal Physiology
Kazan, Russian Federation
diana_bilalova@hotmail.com
Razina R. Nigmatullina
Federal State Budgetary Educational Institution of Higher Education «Kazan Medical University» of the Ministry of Healthcare of the Russian Federation (FSBEI HE Kazan SMU MON Russia)
DB, Professor, Department of Normal Physiology
Kazan, Russian Federation
razinar@mail.ru
Lilia R. Khusnutdinova
Federal State Budgetary Educational Institution of Higher Education «Kazan Medical University» of the Ministry of Healthcare of the Russian Federation (FSBEI HE Kazan SMU MON Russia)
Senior Laboratory Assistant, Department of Hospital Pediatrics
Kazan, Russian Federation
Husnutdinova-lil@mail.ru